AEX Gold have discovered massive copper and gold deposits plus RareEarths/Graphite in Greenland. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Regulatory News (AVCT)

Share Price Information for Avacta (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 109.00
Bid: 107.00
Ask: 111.00
Change: -1.60 (-1.45%)
Spread: 4.00 (3.74%)
Open: 110.00
High: 110.00
Low: 107.00
Prev. Close: 110.60
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Moderna Exercises Exclusive Product License Option

Mon, 4th Feb 2019 07:00

RNS Number : 9010O
Avacta Group PLC
04 February 2019






4 February 2019


Avacta Group plc


("Avacta", the "Group" or the "Company")


Moderna Exercises Option for an Exclusive Product License


Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that ModernaTX, Inc. (NASDAQ: MRNA) has exercised its option to enter into an exclusive licensing agreement with respect to certain Affimers against a potential therapeutic target that has been part of an ongoing research collaboration between the two companies.


In 2015, Avacta and Moderna entered into a collaboration, license and option agreement under which Moderna was granted exclusive access to Avacta's Affimer technology for certain collaboration targets and the option to enter into exclusive license agreements on pre-agreed terms to further research, develop and commercialize Affimers selected by Moderna.


Under the terms of the agreement Avacta may receive undisclosed payments upon future clinical development milestones and royalties in connection with future product sales.


Dr Alastair Smith, Avacta Group Chief Executive Officer, commented:

"I am delighted to report that Moderna has exercised its option to enter into this exclusive license agreement with respect to certain Affimer molecules that have been generated through our collaboration. This is further strong validation of the potential of the Affimer drug platform to generate differentiated therapeutic molecules for development.


We will continue to support Moderna and their development objectives and I look forward to updating the market as and when key development milestones are met."


-Ends -


For further information from Avacta Group plc, please contact:


Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer


Tel: +44 (0) 844 414 0452

finnCap Ltd

Geoff Nash / Giles Rolls - Nominated Adviser

Tim Redfern - ECM


WG Partners

Nigel Birks / Nigel Barnes

David Wilson / Claes Spang




Tel: +44 (0) 207 220 0500



Tel: +44 (0) 203 705 9318

Tel: +44 (0) 203 705 9217


Turner Pope Investments

James Pope

Ben Turner


Zyme Communications (Trade and Regional Media)

Katie Odgaard


Yellow Jersey (Financial Media and IR)

Sarah Hollins

Harriet Jackson

Tel: 020 3621 4120



Tel: +44 (0)7787 502 947



Tel: +44 (0)7764 947137

Tel: +44 (0)7544 275882



About Avacta Group plc (

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.


Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer® technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer® technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.


Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer® reagents through licensing to developers of life sciences research tools and diagnostics.


The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
Date   Source Headline
16th May 202212:00 pmRNSAffyXell expands partnership with GenScript ProBio
11th May 20227:00 amRNSLondon Therapeutics headquarters established
6th May 20227:00 amRNSBlock Listing Application to AIM (update)
28th Apr 20221:53 pmRNSBlock Listing Application to AIM
14th Apr 20225:01 pmRNSIssue of Equity and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.